Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GC012F injection in refractory systemic lupus erythematosus
CTR20242763Phase 2Active
- Sponsor
- Gracell Biotechnologies
- Start
- Aug 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GC012 in systemic lupus erythematosus (SLE), sponsored by Gracell Biotechnologies. Started Aug 2024; status: active.
02
Drugs
GC012
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20242763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242763.